{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009148","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.609915+00:00","generated_at":"2026-06-25T21:10:55.548746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3","bullets":["Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.","On track to initiate Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in Q3 2022.","Presented preclinical data for SZN-413 (retinal vascular diseases) at ARVO showing Wnt activation and vessel regrowth.","Preclinical data for lacrimal gland and lung Wnt modulation highlighted."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009148","json":"https://secwatch.observer/filing/0000950170-22-009148.json","markdown":"https://secwatch.observer/filing/0000950170-22-009148.md","text":"https://secwatch.observer/filing/0000950170-22-009148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/0000950170-22-009148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022009148/srzn-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:10:55.548746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}